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Abstract: A series of water-soluble cationic chitosan derivatives were prepared by 
chemoselective functionalization at the amino group of five different parent chitosans 
having varying degrees of acetylation and molecular weight. The quaternary moieties were 
introduced at different alkyl spacer lengths from the polymer backbone (C-0, C-2 and C-6) 
with the aid of 3,6-di-O-tert-butyldimethylsilyl protection of the chitosan backbone, thus 
allowing full (100%) substitution of the free amino groups. All of the derivatives were 
characterized using 
1
H-NMR, 
1
H-
1
H COSY and FT-IR spectroscopy, while molecular weight 
was determined by GPC. Antibacterial activity was investigated against Gram positive  
S. aureus and Gram negative E. coli. The relationship between structure and activity/toxicity 
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was defined, considering the effect of the cationic group’s structure and its distance from 
the polymer backbone, as well as the degree of acetylation within a molecular weight range 
of 7–23 kDa for the final compounds. The N,N,N-trimethyl chitosan with 100% 
quaternization showed the highest antibacterial activity with moderate cytotoxicity, while 
increasing the spacer length reduced the activity. Trimethylammoniumyl quaternary 
ammonium moieties contributed more to activity than 1-pyridiniumyl moieties. In general, 
no trend in the antibacterial activity of the compounds with increasing molecular weight or 
degree of acetylation up to 34% was observed. 
Keywords: silyl chitosan; trimethyl chitosan (TMC); quaternary ammoniumyl; 
pyridiniumyl derivatives; antibacterial activity; structure-activity relationship (SAR) 
 
1. Introduction 
Chitin is a structural polysaccharide that forms the basic constituent of the outer skeleton  
of insects and crustaceans, including shrimps and crabs. Chitin can be partially or fully deacetylated 
using strong alkali to give chitosan. Chitosan is therefore a heteropolysaccharide comprised of  
2-amino-2-deoxy-D-glucopyranose (glucosamine) and N-acetyl glucosamine units linked through 
(1→4)-β-glycosidic bonds. A number of applications have been found for chitosan in the fields of 
pharmaceutics [1], biomedicine [2], cosmetics [3] and the food industry [4], due to its unique 
combination of various properties, like bioactivity, biocompatibility, biodegradability and lack of 
toxicity [5,6]. 
Amongst its various properties, the antimicrobial efficacy and applications of chitosan against 
bacteria have been the focus of many investigations. Chitosan has limited solubility in aqueous media 
above pH 6. It shows antibacterial properties only in acidic media. This activity is not observed at high 
pH, due to the absence of the positively charged amino groups and also due to low solubility in 
aqueous media [7–9]. Chitosan derivatives, in which permanent positive charges were introduced onto 
the polymer backbone, have been synthesized, which led, in general, to good aqueous solubility and 
also contributed to significant antibacterial activity at neutral pH [10]. Previously, such derivatives 
have been prepared by quaternizing the amino group of native chitosan [11,12] or by introducing the 
quaternized group in one step through an acylation or alkylation reaction [13,14]. This leads to 
products that are heterogeneous with respect to the degree of substitution (DS) on the amino group and 
often partially O-modified [15]. Regioselective triphenylmethyl (trityl) protection of the primary (C-6) 
hydroxyl group of chitosan to give 6-O-trityl chitosan has also been utilized to facilitate the synthesis 
of N-chloroacyl [16,17], N-betaine [18] and quaternary piperazine derivatives of chitosan [19,20]. 
Although the use of such selective protection resulted in higher DS, this led to an increase in  
the number of synthetic steps, and some modification at unprotected hydroxyl groups can also be 
observed [21]. Recently, we reported on silyl protected 3,6-di-O-tert-butyldimethylsilylchitosan  
(diTBDMS-CS) [22,23], which has been utilized in various chemoselective modifications to give 
products like N-(bromoacetyl)-diTBDMS-chitosan, N-(2-(N,N,N-trialkylammoniumyl)-chitosan, 
N,N,N-trimethyl chitosan and chitosan derivatives modified by covalent linking of the highly lipophilic 
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photosensitizer, meso-tetraphenylporphyrin [24,25]. The TBDMS-protected precursor enabled the 
synthesis to be carried out in an organic medium, thereby allowing well controlled and regioselective 
modification, leading to homogenous products that can be fully characterized by spectroscopy with 
techniques, such as 
1
H-NMR, FT-IR, COSY and HSQC. 
The role of the cationic charge in the antimicrobial effect is believed to be associated with the 
binding of the polymer to the bacterial cell wall. Several models have been proposed to explain the 
antimicrobial activity of chitosan, but the most accepted is electrostatic interaction between the 
positive charges on the polymer and the negatively charged anionic components of the bacterial 
surface, which weakens the cell wall and leads to cell lysis [26]. The polycationic structure of chitosan 
is a pre-requisite for antibacterial activity in spite of the structural differences in Gram positive and 
Gram negative bacteria [27]. Removal of the cell wall brings the polymer in contact with the cell 
membrane, thereby affecting membrane permeability and even reversing the surface charge  
of the bacteria [28]. These reactions finally lead to the leakage of the intracellular components, as 
evidenced by increased absorption at 260 nm [28], the increased electrical conductivity of the cell  
suspension [29] and cytoplasmic β-galactosidase release [30–33]. 
The structure-activity relationship (SAR) for chitosan and chitosan derivatives is not well 
understood. The relation between molecular weight (Mw) and degree of acetylation (DA) of chitosan 
to its antibacterial properties has also been explored. While high Mw and degree of quaternization 
(DQ) of N,N,N-trimethyl chitosan chloride (TMC) derivatives showed high bactericidal activity against 
both S. aureus and E. coli [34], in another study, it was reported that low Mw chitosan and its 
derivatives showed better activity [35,36]. A lower DA of acid-soluble chitosan was shown to lead to a 
greater inhibitory effect against S. aureus and E. coli [37–39], while some other studies have not 
shown a clear relationship between DA and the antimicrobial effect of unmodified chitosan [40,41]. 
In the current study, we used five different parent chitosan materials with variations  
in DA and Mw. These materials were used to synthesize different N-modified alkyl quaternary 
ammoniumyl and pyridiniumyl chitosan derivatives, such as (trimethylammoniumyl)acetyl, 
(trimethylammoniumyl)hexanoyl, (1-pyridiniumyl)acetyl, (1-pyridiniumyl)hexanoyl and N,N,N-trimethyl 
chitosan. These quaternary chitosan derivatives were then investigated for their antibacterial effects to 
allow systematic investigation of SAR under conditions where the effect of the functional group and 
the spacer length, as well as variations in the activity with the Mw and DA of the chitosan could  
be observed.  
2. Results and Discussion 
The quaternary ammoniumyl and 1-pyridiniumyl derivatives were synthesized from five different 
chitosan parent materials (denoted in superscript, e.g., i–v) (CSi–v) varying in their DA from 6% to 
34% and from 180 to 308 kDa in their Mw.  
The quaternary groups were distanced from the polymer backbone with alkyl chain spacers.  
Each spacer length required a different approach to the synthesis; the discussion on the synthesized 
derivatives is therefore divided into four sections in accordance with the length of the alkyl chain  
(C-spacer) or its absence.  
  
Mar. Drugs 2014, 12 4638 
 
 
2.1. Synthesis of N-(2-(N,N,N-Trimethylammoniumyl)acetyl)-chitosan Chloride (TMA-CS) and  
N-(2-(1-Pyridiniumyl)acetyl)-chitosan Chloride (PyA-CS), the C-2 Spacer Chitosan Derivatives 
The synthetic route to prepare the final TMA-CS (6
i–v
) and PyA-CS (8
i–v
) is shown in Scheme 1. 
Initially, all five different chitosan materials (1
i–v
) were converted to their corresponding chitosan 
mesylate salts (Mes-CS) (2
i–v
) by careful dropwise addition of methanesulfonic acid to the chitosan 
suspended in water at 10 °C. The finely powdered materials (2
i–v
) were obtained by following our 
earlier reported protocol. Unlike chitosan starting materials (1
i–v
), these mesylates, 2
i–v
, were 
completely soluble in H2O, as well as in organic solvents, such as DMSO. The solubility of Mes-CS in 
DMSO was important, as it facilitated quantitative silyl protection of both hydroxyl groups on the CS 
under homogeneous conditions. Fully silyl-protected diTBDMS-CS (3
i–v
) materials were then obtained 
by using tert-butyl-dimethylsilyl chloride (TBDMSCl) and imidazole in DMSO at 25 °C. The 
intermediate N-(bromoacetyl)-3,6-di-O-TBDMS-chitosan (BrA-diTBDMS-CS) (4
i–v
) was prepared by 
reacting silyl chitosan 3
i–v
 with four equivalents of bromoacetyl bromide in the presence of five 
equivalents of triethylamine (Et3N). The reaction temperature was carefully maintained at −20 °C 
throughout the reaction, and the reaction was quenched after 1 h to avoid any side reactions. The crude 
material was washed with acetonitrile (CH3CN) to afford the fine powdered material, which was 
completely soluble in dichloromethane (CH2Cl2). Freshly prepared reactive intermediate 4
i–v
 was then 
reacted at 25 °C in CH2Cl2, with an excess of NMe3 or pyridine to afford compounds 5
i–v
 and 7
i–v
, 
respectively. Compounds 5
i–v
 and 7
i–v
 were finally deprotected using concentrated (conc) HCl/MeOH to 
afford the corresponding final quaternized chitosan derivatives, 6
i–v
 and 8
i–v
, respectively (Scheme 1). 
Scheme 1. Synthesis of final N-(2-(N,N,N-trimethylammoniumyl)acetyl)-chitosan chloride 
(TMA-CS) (6
i–v
) and N-(2-(1-pyridiniumyl)acetyl)-chitosan chloride (PyA-CS)(8
i–v
) 
derivatives. Reactions and conditions: (a) MeSO3H/H2O (1:1), 10 °C, 1 h (90%);  
(b) tert-butyl-dimethylsilyl chloride (TBDMSCl), imidazole, DMSO, 25 °C, 24 h (96%);  
(c) bromoacetyl bromide, Et3N, CH2Cl2, −20 °C, 1 h (92%); (d) Me3N (31%–35% wt in 
EtOH, 4.2 M),_CH2Cl2,_25 °C, 12 h; (e) pyridine, 25 °C, 24 h; (f) conc HCl/MeOH, 25 °C, 
24 h, ion exchanged by (8%) acqueos NaCl (w/v), 1 h, dialysed against de-ionised water, 48 h. 
 
 
O
O
TBDMSO *
NH
*
O
O
HO *
NH3
* O
O
TBDMSO *
NH2
*OO
HO *
NH2
*
1i-v 2i-v 3i-v
a
OH
OH
OTBDMS
OTBDMS
Br
O
4i-v
O
O
TBDMSO *
NH
*
OTBDMS
N
O
5i-v
Br
O
O
HO *
NH
*
OH
N
O
6i-v
Cl
O
O
TBDMSO *
NH
*
OTBDMS
N
O
7i-v
Br
O
O
HO *
NH
*
OH
N
O
8i-v
Cl
OSO2Me
b
c
d
f e
f
TBDMS = Si
where,
Mar. Drugs 2014, 12 4639 
 
 
1
H NMR and FT-IR analysis. All of the key intermediates and final TMA-CS and PyA-CS 
derivatives were thoroughly characterized. The 
1
H NMR (Figure 1) and FT-IR (Figure 2) overlay 
comparison of chitosan derivatives at different stages of synthesis confirmed the N-selective covalent 
modification with 100% substitution at the free amino groups. 
1
H NMR and IR spectra of silyl 
chitosan (3
i
) and the bromoacyl intermediate (4
i
) showed complete silyl protection of both hydroxyls 
(C-3 and C-6). 
1
H NMR (Figure 1B,C) and FT-IR of 4
i
 (Figure 2C) showed characteristic amide bond 
peaks (1676, 1527 cm
−1
) with no sign of ester functionality, as expected for N-selective modification. 
Characteristic TBDMS peaks indicated by red arrows at 1259, 778 and 837 cm
−1
 and C-H peaks at 
2858–2956 cm−1 remained intact. The final derivatives, TMA-CS (6i) and PyA-CS (8i), were 
completely soluble in D2O (Figure 1D,E) after the removal of the TBDMS peaks, as seen by their 
absence in the NMR and FT-IR spectra (Figure 2D,E). 
Figure 1. 
1
H NMR spectra overlay of the main compounds and final C-2 spacer quaternary 
derivatives of the representative chitosan material (CS-i, 7%_DA): (A) chitosan mesylate 
salts (Mes-CS), 2
i
; (B) diTBDMS-CS, 3
i
; (C) N-(bromoacetyl)-3,6-di-O-TBDMS-chitosan 
(BrA-diTBDMS-CS), 4
i
; (D) TMA-CS, 6
i
; (E) PyA-CS, 8
i
. 
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Figure 2. FT-IR spectra overlay of the main compounds and final C-2 spacer quaternary 
derivatives of the representative chitosan material (CS-i, 7%_DA): (A) Mes-CS, 2
i
;  
(B) diTBDMS-CS, 3
i
; (C) BrA-diTBDMS-CS, 4
i
; (D) TMA-CS, 6
i
; (E) PyA-CS, 8
i
.  
 
Synthesis of C-3 and C-5 spacer chitosan derivatives: An attempt to synthesize C-3 and C-5 spacer 
derivatives using 3-chloropropionyl chloride and 5-chlorovaleroyl chloride, respectively, under similar 
conditions did not succeed. This may be explained by the formation of stable four- or  
six-membered ring compounds by the intermediate (Figure 3), which will be favored according to 
Baldwin’s rules for favorable ring closure of four-, five- or six-membered rings [42]. Stirling et al. (1960) 
have reported the mechanism of similar intramolecular cyclization of bromo-amides under basic or neutral 
conditions [43]. The cyclization was indicated in the 
1
H NMR spectra of the chloroacyl-intermediates, 
where the final deprotected material having the C-3 and C-5 spacer was not soluble in water, indicating 
that the desired quaternized product was not obtained. The FT-IR analysis (data not shown) of these 
materials also indicated ring fusion (Figure 3), similar to what was described by Stirling et al. [43]. 
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Figure 3. Possible intramolecular cyclization of C-3, C-4 and C-5 spacer compounds based 
on the findings of Stirling et al. [43]. 
 
2.2. Synthesis of N-(6-(N,N,N-Trimethylammoniumyl)hexanoyl)-chitosan Chloride (TMHA-CS) and  
N-(6-(1-Pyridiniumyl)hexanoyl)-chitosan Chloride (PyHA-CS), C-6 Spacer Derivatives 
The derivatives, N-(6-(N,N,N-trimethylammoniumyl)hexanoyl)-chitosan chloride (TMHA-CS)  
(11
i–v
) and PyHA-CS (13
i–v
), were synthesized (Scheme 2) under conditions similar to those used for 
the C-3 spacer compounds, with slight modifications. The key electrophilic intermediate, 9
i–v
, was 
prepared by reacting silyl chitosan 3
i–v
 with four equivalents of 6-bromohexanoyl_chloride in the 
presence of five equivalents of Et3N at −20 °C for 1 h, under almost identical conditions as those described 
for similar key intermediates with the C-2 spacer, i.e., 4
i–v
. Intermediate 9
i–v
 was also completely soluble in 
CH2Cl2. However, unlike intermediate 4
i–v
, 9
i–v
 was found to be more stable and, hence, need not be used 
immediately after its preparation. The intermediate 9
i–v
 was confirmed by 
1
H NMR and FT-IR analysis. 
Intermediate 9
i–v
 when reacted with an excess of NMe3 or pyridine, afforded the corresponding 
compounds 10
i–v
 and 12
i–v
, respectively. However, the reaction with NMe3 and/or pyridine appeared to 
be slower in case of the C-6 spacer as compared to the shorter spacer (C-2), and thus, potassium iodide 
(KI) was used as a catalyst to assist the reaction along with prolonged reaction time. Crude compounds 
10
i–v
 and/or 12
i–v
 were then subjected to final deprotection with conc HCl/MeOH at 25 °C, and the 
materials were ion-exchanged using aqueous NaCl (5%–8%) (w/v), dialyzed and freeze dried to afford 
the corresponding final TMHA-CS (11
i–v
) and PyHA-CS (13
i–v
) derivatives, respectively. The 
trimethylammoniumyl derivatives solubilized faster in water compared to the pyridinium derivatives. 
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Scheme 2. Synthesis of final N-(6-(N,N,N-trimethylammoniumyl)hexanoyl)-chitosan 
chloride (TMHA-CS) (11
i–v
) and PyHA-CS (13
i–v
) derivatives. Reactions and conditions:  
(a) 6-bromohexanoyl chloride, Et3N, CH2Cl2, −20 °C, 1 h (69%); (b) Me3N (31%–35% wt 
in EtOH, 4.2 M), KI, CH2Cl2, 25 °C, 48 h; (c) pyridine, KI, 25 °C, 48 h; (d) conc 
HCl/MeOH, 25 °C, 24 h, ion exchange by (5%–8%) NaCl (aqueous) (w/v), 1 h, dialysed 
against de-ionised water, 48 h. 
 
1
H NMR and FT-IR analysis: Synthesis of the C-6 spacer compounds was followed by 
1
H NMR 
(Figure 4) and FT-IR (Figure 5) analysis. In the 
1
H NMR of diTBDMS-CS (3
iv
) in CDCl3 (Figure 4B), 
the broadening of individual backbone peaks could be seen. This can be attributed to the increased 
viscosity of the material. The 
1
H NMR spectra of BrHA-diTBDMS-CS (9
iv
) (Figure 4C) showed that 
the backbone peaks (H-1 to H-6′) appeared together while the CH2 peaks of the alkyl chain, N-acetyl 
peak and TBDMS peaks could be assigned individually. Furthermore, FT-IR spectra of 3
iv
 (Figure 5B) 
and 9
iv
 (Figure 5C) confirmed the characteristic TBDMS peaks (shown in red arrows) and amide peaks 
(in blue arrows). The final C-6 spacer derivatives, TMHA-CS (11
iv
) (Figure 4D) and PyHA-CS (13
iv
) 
(Figure 4E) could also be confirmed by their individual distinct peaks. The spectra confirmed 100% 
substitution of the amino groups by either trimethylammoniumyl or 1-pyridiniumyl moieties. The IR 
spectra (Figure 5D,E) also confirmed the deprotection. 
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Figure 4. 
1
H NMR spectra overlay of the main compounds and final C-6 spacer quaternary 
derivatives of the representative chitosan material (CS-iv, 19%DA): (A) Mes-CS (2
iv
);  
(B) diTBDMS-CS (3
iv
); (C) BrHA-diTBDMS-CS (9
iv
); (D) TMHA-CS (11
iv
);  
(E) PyHA-CS (13
iv
). 
 
Figure 5. FT-IR overlay of the main compounds and final quaternary derivatives of the 
representative chitosan material (CS-iv, 19%_DA): (A) Mes-CS (2
iv
); (B) diTBDMS-CS (3
iv
);  
(C) BrHA-diTBDMS-CS (9
iv
); (D) TMHA-CS (11
iv
); (E) PyHA-CS (13
iv
).  
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2.3. Synthesis of C-0 Spacer TMC Derivatives (15
i–v
) 
N,N,N-trimethyl-chitosan (TMC) was synthesized according to the procedure developed by 
Benediktsdottir et al. [25] as shown in Scheme 3. Briefly, diTBDMS-CS (3
i–v
) was dispersed in  
N-methyl-2-pyrrolidone (NMP), and methylation was carried out using methyl iodide (CH3I) in the 
presence of cesium carbonate (Cs2CO3) as a base. This method resulted in 100% trimethyl substitution at 
the amino group without any O-methylation. The excess CH3I and NMP used in the reaction were 
removed by dialyzing the material against deionized water followed by freeze-drying. The  
N,N,N-trimethyl-diTBDMS-CS iodide (14
i–iv
) was then subjected to deprotection of the silyl groups 
under 1M tetrabutyl ammonium fluoride (TBAF)/NMP solution. In cases where traces of the silyl 
groups still remained in the polymer, the deprotection was repeated under the same conditions. The 
products were then characterized using 
1
H-NMR, 
1
H-
1
H COSY and IR spectra. The appearance of a 
new peak at 3.64 ppm in N,N,N-trimethyl-diTBDMS-CS indicated the trimethyl substitution in the 
polymer. However, due to the presence of the diTBDMS groups, the peaks were broadened and the 
exact DS was difficult to determine. Only after removal of the silyl groups did the polymer peaks 
became sharper, so the DS could be calculated from the integrals of H-1 (5.49 ppm) and the trimethyl 
(3.35 ppm) peak. 
Scheme 3. Synthetic route for N,N,N-trimethyl chitosan chloride (TMC) derivatives (15
i–v
). 
Reactions and conditions: (a) CH3I, Cs2CO3, NMP, 45–50 °C; (b) TBAF (1 M), NMP, 50 °C.  
 
2.4. Physicochemical Properties of Chitosan-Derivatives 
The DA was calculated by 
1
H NMR analysis of the parent chitosan materials. The weight average 
molecular weight (Mw) of parent chitosan materials, Mes-CS and the final quaternized derivatives of 
the chitosan were determined by gel permeation chromatography (GPC) (Table 1).  
Table 1. Physical properties of chitosan derivatives. 
Parent 
Chitosan 
Material 
DA 
(%) 
Chitosan  
(1
i–v
) 
Mes-CS  
(2
i–v
) 
TMA-CS  
(6
i–v
) 
PyA-CS  
(8
i–v
) 
TMHA-CS 
(11
i–v
) 
PyHA-CS 
(13
i–v
) 
TMC  
(15
i–v
) 
Mw (PDI) Mw (PDI) Mw (PDI) Mw (PDI) Mw (PDI) Mw (PDI) Mw (PDI) 
CS-i 7 235 (2.8) 24.6 (1.6) 23.8 (2.1) 18.8 (1.8) 17.3 (1.6) 12.9 (1.5) 18.7 (1.5) 
CS-ii 6 294 (2.3) 20.8 (1.9) 17.1 (1.8) 17.3 (2.0) 15.1 (1.5) 9.8 (1.3) 15.3 (1.4) 
CS-iii 17.3 225 (2.6) 19.1 (1.6) 16.4 (1.6) 12.2 (1.9) 13.1 (1.4) - - 13.2 (1.4) 
CS-iv 19 308 (2.6) 21.4 (2.4) 16.7 (1.6) 14.6 (1.8) 14.2 (1.8) 15.8 (1.1) 19.8 (1.6) 
CS-v 34.2 180 (2.9) 19.5 (1.5) 18.9 (1.7) 10.8 (1.4) 7.4 (1.4) - - 16.5 (1.5) 
The average molecular weight (Mw) is in kDa, and the polydispersity index is abbreviated as (PDI). DA = degree of acetylation. 
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Though the parent chitosan (CS-i to CS-v, 1
i–v
) has a higher range of Mw (180–308 kDa), 
significant degradation of the polymer chain was observed after their conversion to the corresponding 
mesylate salts (2
i–v
) in all five materials, as this step requires highly acidic conditions, which are 
known to cause hydrolysis of glycosidic bonds in the polymer backbone [44]. Any further degradation 
after the first step was limited; so, although the Mw values were reduced, the relative range of Mw  
(7–23 kDa) for the derivatives was comparable to that of the starting chitosan materials. 
2.5. Antibacterial Properties 
The antibacterial activities of the quaternary chitosan derivatives were determined by measuring the 
minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC) values against  
S. aureus and E. coli. The derivatives varied in their quaternary group, in the length of the spacer 
bearing the quaternary group, Mw and also in the DA of the chitosan. These parameters were used to 
observe the influence of the chitosan polymer on the antibacterial properties in order to develop an 
overall structure-activity relationship. The quaternary derivatives carrying positive charges were highly 
soluble in water, and hence, their activity could be tested at neutral pH. Table 2 shows that the chitosan 
derivatives exerted an antibacterial effect against both bacterial strains, with S. aureus yielding lower 
MIC and MLC values compared to E. coli. With respect to the variation in the functional group and the 
length of the spacer carrying the functional group, the following trend in activity was observed:  
TMC derivatives (15
i–15v) exhibited the highest antibacterial effect against both strains, with MIC 
values ranging from 4 to 32 μg/mL against S. aureus and 64 to 256 μg/mL against E. coli, respectively. 
These results were consistent with earlier studies where TMC (DS = 0.86) was found to have a MIC of 
8 μg/mL and 128 μg/mL against S. aureus and E. coli, respectively [45]. Thus, the degree of 
trimethylation does not seem to have a pronounced effect on antibacterial activity, as the DS increased 
from 0.86 to 0.95. The activity of the series of TMA-CS derivatives (6
i–6v) was comparable to that of 
the TMC derivatives against S. aureus, but was much lower against E. coli. These derivatives showed 
similar activity as the previously synthesized TMA-CS derivatives (DS = 0.8; MIC = 128 and  
≥8192 μg/mL against S. aureus and E. coli, respectively) [45]. The TMHA-CS derivatives (11i–11v) 
with a C-6 spacer had still lower activity against S. aureus (MIC = 1024–2048 μg/mL) compared to the 
other two series carrying the same quaternary group. However, their activity was found to be higher 
than that of the TMAC-CS derivatives against E. coli (MIC = 128–1024 μg/mL). Thus, in most cases, 
a decreasing effect on activity could be observed as the spacer between the trimethylammonium group 
and the polymer increased. The second functional group, i.e., a pyridinium moiety attached to 
polymers having an acetyl (PyA-CS) or a C-6 spacer (PyHA-CS), also showed bactericidal  
activity against S. aureus; however, they were found to be less effective than their corresponding 
trimethylammonium derivatives. The acetyl pyridinium moiety exhibited MIC values of  
512–1024 μg/mL against S. aureus, while the activity against E. coli was lower, with the MIC ranging 
from 128 to 16,384 μg/mL. The C-6 spacer derivative, as expected, showed still less activity than the 
acetyl pyridinium derivatives against both strains. They were active only against S. aureus  
(MIC = 2048–8192 μg/mL) while remaining almost inactive against the Gram negative E. coli within 
the range of concentrations measured. These results are in agreement with our previous investigations, 
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where our results indicated that antimicrobial action was more efficient when the cationic charge is 
located at the amino group of the chitosan and not on the quaternary substituent [46]. 
Table 2. Antibacterial activity, hemolytic activity and cytotoxicity of the quaternary 
chitosan derivatives. 
Compounds Structure 
S. aureus (ATCC 29213) E. coli (ATCC 25922) 
HC50 
(μg/mL) 
Selectivity (HC50/MIC) 
EC50 
(μg/mL) 
MIC 
(μg/mL) 
MLC 
(μg/mL) 
MIC 
(μg/mL) 
MLC 
(μg/mL) 
S. aureus E. coli 
TMC (15i) 
 
8 64 256 256 6114 764 47.7 40 
TMC (15ii) 32 32 64 64 6114 191 95.5 - 
TMC (15iii) 4 4 64 64 6114 1528 95.5 - 
TMC (15iv) 8 8 256 256 3072 764 47.7 10 
TMC (15v) 32 32 256 1024 640 191 - - 
TMA-CS (6i) 
 
8 8 16,384 ≥32,768 ≥32,768 ≥4096 ≥2 26 
TMA-CS (6ii) 8 8 16,384 16,384 ≥32,768 ≥4096 ≥2 - 
TMA-CS (6iii) 32 32 16,384 16,384 ≥32,768 ≥1024 ≥2 - 
TMA-CS (6iv) 32 32 ≥32,768 ≥32,768 ≥32,768 ≥1024 - 66 
TMA-CS (6v) 128 128 ≥32,768 ≥32,768 ≥32,768 ≥256 - - 
PyA-CS (8i) 
 
8 1024 16,384 16,384 ≥32,768 ≥8192 ≥2 38 
PyA-CS (8ii) 8 512 8192 8192 ≥32,768 ≥8192 ≥4 - 
PyA-CS (8iii) 1024 1024 16,384 16,384 ≥32,768 ≥8 ≥2 - 
PyA-CS (8iv) 512 1024 16,384 16,384 ≥32,768 ≥16 ≥2 12 
PyA-CS (8v) 512 512 128 8192 ≥32,768 ≥64 ≥256 - 
TMHA-CS (11i) 
 
1024 2048 256 ≥32,768 ≥32,768 ≥32 ≥128 644 
TMHA-CS (11ii) 2048 2048 512 16,384 ≥32,768 ≥16 ≥64 - 
TMHA-CS (11iii) 1024 2048 128 ≥32,768 ≥32,768 ≥4 ≥256 - 
TMHA-CS (11iv) 2048 4096 512 ≥32,768 ≥32,768 ≥8 ≥64 108 
TMHA-CS (11v) 1024 4096 1024 ≥32,768 ≥32,768 ≥32 ≥32 - 
PyHA-CS (13i) 
 
4096 4096 ≥32,768 ≥32,768 ≥32,768 ≥8 - 4 
PyHA-CS (13ii) 2048 2048 ≥32,768 ≥32,768 ≥32,768 ≥32 - - 
PyHA-CS (13iii) 8192 8192 ≥32,768 ≥32,768 ≥32,768 ≥4 - - 
PyHA-CS (13iv) 2048 2048 16,384 16,384 ≥32,768 ≥16 ≥2 18 
PyHA-CS (13v) 2048 2048 ≥32,768 ≥32,768 ≥32,768 ≥16 - - 
The antibacterial tests was done according the Clinical and Laboratory Standards Institute (CLSI) protocol (see Section 3.4.1). According to this procedure, 
a single dilution series was done for each compound, and gentamycin was used as a positive control. A difference of 1–2 dilutions is therefore not 
considered significant. The hemolysis measurements were also done in singlets for each concentration. The cytotoxicity measurements were carried out in 
triplicate, and the standard deviation varied from 10% to 22%. 
The effect of the DA and Mw of the chitosan on its antibacterial properties was also investigated. 
Chitosan derivatives carrying a particular functional group varied in their molecular weight and degree 
of acetylation. Although the staring chitosan samples had Mw variations from 180 to 308 kDa, due to 
degradations during the synthesis process, all of the derivatives showed considerably less Mw  
(7–23 kDa), but the relative range in Mw was not reduced. However, no trend in activity of the 
derivatives with variation in Mw could be observed. Hence, the difference was mainly based on the 
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DA variation. Earlier studies reported different conclusions regarding the dependency of the 
antimicrobial activity of chitosan on the DA and Mw. One study of the antibacterial activity of 
chitosan indicated that low molecular weight chitosan (4.1–5.6 kDa) showed a greater inhibitory effect 
when the DA, ranging from 0.45–0.52, was reduced to 0.17–0.19 [47]. Again, in another study, the 
antibacterial activity was found to be independent of variation in the Mw (2–224 kDa) of chitosan, but 
to decline with increasing DA from 0.16 to 0.48 [48]. Figure 6A,B shows the variation in antibacterial 
activity (log 1/MIC) of the quaternary derivatives with DA against S. aureus and E. coli. In contrast, as 
seen in Figure 6B, only Series 8 showed an apparent increase in antibacterial activity (7–10-fold) 
against E. coli as the DA values increased from 19% to 34.2%. However when the MLC values are 
considered (Table 2), there is only one dilution difference in this series. For the Series 15 and 6, the 
activity seemed to decrease gradually, as the DA changed from 6%–34% with only a 2–3-fold decrease 
in activity. In contrast, the activity of Series 11 and 13 remained independent of variations in DA 
against S. aureus. In Figure 6B, it can be observed that the activities of the compounds differed by only 
1–2 dilutions, and no clear variation in activity with increasing or decreasing DA was observed. Thus, 
the activity of the complete series against E. coli remained independent of variations in DA. 
Figure 6. Variation in the antibacterial activity of chitosan with different DA against  
(A) S. aureus and (B) E. coli.  
 
The error bars indicate a deviation equivalent to one dilution. 
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The screening of the quaternary compounds against the two strains of bacteria and their results led 
us to the conclusion that the antibacterial activity of the chitosan derivatives decreased as the distance 
of the positive charge from the polymer backbone increased. This was observed for the 
trimethylammonium, as well as the pyridinium functional group. Thus, the antibacterial activity of the 
chitosan polymer not only depended on the number of positive charges present in the polymer, but also on 
the positioning of the positive charge on the polymer backbone. It has been earlier observed that the 
activities of other antimicrobial polymers with a synthetic backbone were dependent on the spacer length 
due to changes in the charge density and conformation of the polymer, which, in turn, affects its interaction 
with the bacterial membrane [49]. A study of the interaction of chitosan with model membranes has 
also shown that the mode of action of chitosan is not only related to electrostatic interactions, but also 
to its specific conformation in solution [50]. This may explain why the TMC derivatives showed the 
highest activity. In this case the positive charge was located on the polymer backbone, which may be 
favorable for the conformation required for binding to the bacterial membrane. However, as the spacer 
length increases, the polymer probably will tend to adopt a conformation that is less favorable for 
efficient binding with the anionic components of the bacterial membrane, and hence, the activity reduces. 
All of the quaternary chitosan derivatives showed greater activity, in general, against Gram positive  
S. aureus than Gram negative E. coli. This is in agreement with a previous observation where 
unmodified chitosan was shown to exhibit greater inhibitory effects against Gram positive bacteria as 
compared to Gram negative bacteria [51] due to differences in the cell wall structure [35]. In the case of 
Gram positive bacteria, the positive charges on chitosan were thought to bind to the thick 
peptidoglycan cell wall of the bacteria, resulting in cell wall disruption and leakage of the cellular 
contents. On the other hand, Gram negative bacteria possess an additional outer membrane composed 
of lipopolysaccharides, which provide the bacterium with a hydrophilic surface. The anionic units of 
the lipopolysaccharide form ionic type bonds with the cationic groups of the chitosan, which prevents 
nutrient flow and ultimately leads to the death of the cell due to depletion of nutrients [31,52]. Since 
the outer membrane serves as a penetration barrier against macromolecules and hydrophobic 
substances, overcoming the outer membrane barrier is a pre-requisite to displaying activity against 
Gram negative bacteria [29]. 
2.6. Hemolytic Activity and Cytotoxicity 
To determine their toxicity, the compounds were tested for hemolytic activity against human red 
blood cells, and cytotoxicity was measured against the Caco-2 cell line. The antibacterial chitosan 
derivatives were not targeted for a specific organ, and hence, the compounds were evaluated only to 
get a general overview of potential toxicity. These compounds could be considered for surface 
treatments or as disinfectants and, therefore, were tested for hemolysis and the effect on a commonly 
used cell line (Caco-2) derived from mucosal epithelium. As seen in Table 2, the TMC derivatives 
(15
i–15v), which showed the highest antibacterial activity, displayed low hemolytic activity ranging 
from 640 to 6114 μg/mL. The toxicity of the compounds against RBC decreased with decreasing DA of 
the derivatives within the series. However, no particular trend in HC50 values with Mw variations could 
be observed for the TMC series. Light microscopic images of red blood cells (RBC) treated with 
different concentrations of one polymer (15
iii
) are shown in Figure 7. Figure 7A shows a microscopic 
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image of normal RBC suspended in TBS. When the RBCs were treated with different concentrations 
(512 μg/mL and 8,192 μg/mL) of the TMC derivative 15iii, no hemolytic effect was observed with the 
lower concentration (512 μg/mL), as seen in Figure 7B, while the higher concentration (8192 μg/mL) 
produced the deformation of cell shape, as seen in Figure 7C. In Figure 7D, 100% hemolysis was 
observed with the release of hemoglobin when the cells were treated with the positive control  
Triton-X100. TMA-CS and some of the PyA-CS derivatives that showed comparable antibacterial 
activity to that of TMC did not show any hemolytic activity. The compounds in the other two series 
with the C-6 spacer also remained non-hemolytic within the measured concentration range. Thus, the 
ability of the polymers to lyse RBCs diminished as the quaternary group moved away from the 
polymer backbone.  
The cell line cytotoxicity results, on the other hand, differed from those for hemolysis. TMA-CS 
showed cell toxicity at lower concentrations (10–40 μg/mL) compared to hemolysis. Compounds 
containing the trimethylammonium group with a spacer, i.e., the TMA-CS (6
i–6v) and TMHA-CS 
derivatives (11
i–11v), were less cytotoxic compared to the TMC derivatives, while compounds 
containing the pyridinium group, i.e., PyA-CS (8
i–8v) and PyHA-CS (13i–13v), displayed cytotoxicity 
values comparable to those of TMC derivatives. No trend in the cytotoxicity of the compounds with 
changes in the length of the spacer could be observed. However, for most of the compounds, within a 
series, the toxicity was found to be lower in cases having a lower DA. The cytotoxicity was also found 
to be related to the Mw of the derivatives. Compounds having a lower Mw value within a series were 
found to exhibit lower cytotoxicity values. In many studies, antibacterial potency and an agent’s 
selectivity for bacteria over mammalian cells are quantified by determining the MIC and hemolytic 
activity (HC50 values) [53]. In our study, we saw that, although the compounds displayed low hemolytic 
activity, their cellular toxicity was found to be significant. Thus, in order to get a full picture of their 
potential toxicity, only testing compounds against erythrocytes is not sufficient, and more in-depth 
studies of potentially toxic effects against various cell types in vitro or in vivo should be a requirement. 
Figure 7. Light microscopic images of RBC. (A) RBC suspended in TBS; (B) RBC treated 
with Compound 15
iii
 (512 μg/mL); (C) RBC treated with Compound 15iii (8192 μg/mL); 
and (D) RBC treated with 1% (v/v) Triton-X100.  
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3. Experimental Section  
3.1. Materials 
Five different parent chitosan materials provided by Genis ehf (Reykjavik, Iceland): (i) (CS-i 
(G030626-2) (Mw = 235 kDa, PDI = 2.8, DA = 0.07)); (ii) (CS-ii (S030626-2) (Mw = 294 kDa, PDI = 2.3, 
DA = 0.06)); (iii) (CS-iii (TM1238) (Mw = 225 kDa, PDI = 2.6, DA = 0.17)); (iv) (CS-iv (TM1534) 
(Mw = 308 kDa, PDI = 2.6, DA = 0.19)); and (v) (CS-v (S040108-1) (Mw = 180 kDa, PDI = 2.9,  
DA = 0.34)) were used for synthesis. All chemicals (procured from Sigma-Aldrich
®
) were used as 
received, except solvents, like DMSO, CH2Cl2 and NMP, which were stored over molecular sieves 
before use. Dialysis membranes obtained from Spectrum
®
 Laboratories Inc. (Breda, The Netherlands ,) 
(RC, Spectra/Por, Mw cutoff 3500 Da) and Float-A-Lyzers (Spectra/Por, Mw cutoff 3.5–5 kDa, 5-mL 
sample volume) were used for the dialysis of the final quaternary chitosan derivatives. 
3.2. Characterization and Calculations 
1
H NMR, 
1
H-
1
H COSY samples were recorded with a Bruker AVANCE 400 instrument (Bruker 
Biospin GmbH, Karlsruhe, Germany) operating at 400.13 MHz at 298 K. NMR samples were prepared 
in either CDCl3 or D2O in concentrations ranging from 10 to 15 mg/mL. Chemical shifts were reported 
relative to the deuterated NMR solvents: for CDCl3 (7.26 ppm); whereas in the case of D2O as a 
solvent, the acetone (2.22 ppm) peak was used as the internal reference. IR measurements were 
performed with an AVATAR 370 FT-IR instrument (Thermo Nicolet Corporation, Madison, WI, USA) 
with 32 scans and a resolution of 4 cm
−1
. Samples were mixed thoroughly with KBr and then pressed 
into pellets with a Specac compressor (Specac Inc., Smyrna, GA, USA). Equivalent quantities of 
reagents were calculated on the basis of per glucosamine monomer unit. The degree of substitution for 
acetylation (DA) of CS-(i–v) was estimated by following Equation (1) using 1H NMR spectra of the 
corresponding parent chitosans (1
i–v
).  
    
   
           
       (1) 
3.3. Gel Permeation Chromatography (GPC) 
GPC analysis was used for Mw determination of chitosan, chitosan mesylate and the final 
quaternary alkyl or acyl derivatives of chitosan. GPC measurements were performed using the 
Polymer Standards Service (PSS) GmbH, Mainz, Germany, WinGPCUnichromon Dionex HPLC 
system equipped with a series of three columns (Novema 10 μ guard (50 × 8 mm), Novema 10 μ 30 Å 
(150 × 8 mm) and Novema 10 μ 1000 Å (300 × 8 mm)) (PSS GmbH, Mainz, Germany) and PSS’s 
ETA-2010 viscometer and Shodex RI-101 detectors (Shodex/Showa Denko Europe GmbH, Munich, 
Germany) using the Dionex Ultimate 3000 HPLC system (Thermo Scientific-Dionex Softron GmbH, 
Germering, Germany), Dionex Ultimate 3000 HPLC pump and Dionex Ultimate 3000 autosampler 
(Thermo Scientific-Dionex Softron GmbH, Germering, Germany). WINGPC Unity 7.4 software (PSS 
GmbH, Mainz, Germany) was used for data collection and processing. The eluent for the CS starting 
materials and all synthesized materials was 0.1 M NaCl + 0.1% TFA in Millipore water, and the 
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standards used for the universal calibration curve were poly(2-vinylpyridine) (provided by the PSS-kit) 
(PSS GmbH, Mainz, Germany) with varying average molecular weight. All samples were dissolved in 
the same eluent as mentioned above, filtered through a 0.45-μL filter (Spartan 13/0.45 RC, Whatman 
GmBH, Dassel, Germany) before measurement, and the measurements were carried out at 25 °C using a 
flow rate of 1 mL/min and a 100 μL sample volume. 
3.4. Chemical Synthesis 
3.4.1. General Procedure for N-Quaternized-acetyl-chitosan Derivatives 
Silyl chitosan 3
i–v
 was prepared from chitosan mesylate (Mes-CS) (2
i–v
) using a previously reported 
procedure [22]. Silyl chitosan 3
i–v
 (2.6 mmol) was treated with Et3N (13 mmol) and bromoacetyl 
bromide (10 mmol) in dry CH2Cl2 (15 mL) under N2 atmosphere at −20 °C for 1 h. Concentration  
in vacuo followed by trituration with CH3CN afforded N-(bromoacetyl)-3,6-di-O-TBDMS-chitosan 
(BrA-diTBDMS-CS) (4
i–v
). Compound 4
i–v
 was then treated with excess of Me3N or pyridine to  
afford N-(2-(N,N,N-trimethylammoniumyl)acetyl)-3,6-di-O-TBDMS-chitosan bromide (5
i–v
) and  
N-(2-(1-pyridiniumyl)acetyl)-3,6-di-O-TBDMS-chitosan bromide (7
i–v
), respectively. 
3.4.2. General Procedure for N-Quaternized-hexanoyl-chitosan Derivatives 
Silyl chitosan 3
i–v
 (1.3 mmol) was treated with Et3N (6.5 mmol) and 6-bromohexanoyl chloride  
(5.2 mmol) in dry CH2Cl2 (15 mL) under N2 atmosphere at −20 °C for 1 h. Concentration in vacuo 
followed by trituration with CH3CN afforded N-(6-bromohexanoyl)-3,6-di-O-TBDMS-chitosan 
(BrHA-diTBDMS-CS) (9
i–v
). Compound 9
i–v
 was then treated with an excess of either Me3N  
or pyridine to afford N-(6-(N,N,N-trimethylammoniumyl)hexanoyl)-3,6-di-O-TBDMS-chitosan 
bromide/iodide (10
i–v
) and N-(6-(1-pyridiniumyl)hexanoyl)-3,6-di-O-TBDMS-chitosan bromide/iodide 
(12
i–v
), respectively. 
3.4.3. General TBDMS Deprotection Procedure to Give the Final Quaternary Ammoniumyl and 
Pyridiniumyl Derivatives (6
i–v
, 8
i–v
, 11
i–v
, 13
i–v
) 
The compounds (5
i–v
, 7
i–v
, 10
i–v
 or 12
i–v
) were stirred in MeOH (4–5 mL) and conc HCl (1–2 mL) 
for 12 h at 25 °C. Purification was done by dialysis followed by freeze-drying to afford the 
corresponding quaternized product (6
i–v
, 8
i–v
, 11
i–v
 or 13
i–v
).  
3.4.4. General Procedure for N-Quaternized-chitosan 
Silyl chitosan 3
i–v
 (3.6 mmol) was treated with cesium carbonate (Cs2CO3) (14.2 mmol) and CH3I 
(17.8 mmol) in dry NMP (20 mL) at 50 °C for 48 h. Precipitation in ice-cold water followed by 
filtration afforded N,N,N-trimethyl-3,6-di-O-TBDMS-chitosan iodide (14
i–v
). Compound 14
i–v
  
(3.30 mmol) was then deprotected by treatment with tetrabutyl ammonium fluoride (TBAF) (1 molar) 
solution in NMP (10 mL) at 50 °C for 48 h. Purification was done by dialysis followed by  
freeze-drying to afford N,N,N-trimethyl chitosan chloride (TMC) (15
i–v
). 
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Note: details of all experimental procedures with assignments of 
1
H NMR spectra are available in 
the Supplementary Information.  
3.5. Biological Methods 
3.5.1. Bacterial Strains, Media and Culture Conditions 
The antibacterial tests were assayed according to standard Clinical and Laboratory Standards 
Institute (CLSI) methods for antimicrobial dilution susceptibility tests [54]. Minimum inhibitory 
concentration (MIC) and minimum lethal concentration (MLC) values were measured against 
Staphylococcus aureus (S. aureus, ATCC 29213) and Escherichia coli (E. coli, ATCC 25922) obtained 
from the American Type Culture Collection, representing Gram positive and Gram negative bacteria 
that are susceptible to routinely measured antibiotics. The broth microdilution method was used to 
determine the MIC values using Mueller-Hinton Broth (Oxoid, Hampshire, UK) at pH 7.2 as the 
medium. Blood agar (heart infusion agar (Oxoid) with 5% (v/v) defibrinated horse blood) was used for 
the measurement of MLC. The samples were prepared by dissolving chitosan derivatives in sterile water 
to an initial concentration of 32,768 μg/mL. Fifty microliters of each sample were added to the first two 
wells on a micro-titer plate, and two-fold dilutions were done in 50 μL of Mueller-Hinton broth from 
well two on. This gave a final range varying from 16,384 μg/mL to 16 μg/mL, with the option of reporting 
32,768 μg/mL as the highest concentration. Gentamicin was used as the positive control during the test. 
Bacterial solution of 0.5 McFarland suspension (1–2 × 108 CFU/mL) was prepared by direct colony 
suspension in Mueller-Hinton broth and further diluted 100-fold so as to achieve a final test 
concentration of bacteria of approximately 1 × 10
6
 CFU/mL (or 5 × 10
5
 CFU/well in the microtiter 
plate). The microtiter plates were then incubated at 35 °C for 18 h under moistened conditions. The 
MIC value was defined as the lowest concentration of the antibacterial agent that completely inhibited 
visible growth of the microorganism in the microtiter plate. For MLC measurement, 10 μL × 2 of each 
of the dilutions that showed no visible growth were plated on a blood agar plate and incubated at 35 °C 
for 18 h. MLC was defined as the lowest concentration that achieved a 99.9% decrease in viable cells. 
3.5.2. Hemolytic Activity 
Hemolysis assays were performed according to previously published procedures [55,56] with slight 
modification. Human red blood cell concentrate having an RBC of 6.45 × 10
12
/L, total hemoglobin of 
201 g/L and WBC of 0.15 × 10
9
/L was used for testing the hemolytic activity of the CS derivatives. 
RBCs (100 μL) were suspended in 10 mL of TBS (pH = 7.2). The polymer solutions were prepared in 
TBS at an initial concentration of 32,768 μg/mL and serially diluted 2-fold in a 96-well plate, so as to 
have a minimum concentration of 16 μg/ mL. One hundred microliters of RBC suspension were added 
to 100 μL of the polymer solutions and incubated at 37 °C with light shaking for 30 min. Cells treated 
with TBS and 1% Triton-X100 were used as negative and positive controls, respectively. The cell 
suspensions were centrifuged at 1500 rpm for 10 min, and the supernatant was collected to measure the 
absorbance of the released hemoglobin at 540 nm on a Thermo Scientific Multiscan Spectrum Photometer. 
The percentage hemolysis was calculated using the following equation: 
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       (2) 
where A = absorbance of the polymer solutions, A0 = absorbance of negative control and  
A100 = absorbance of positive control. 
3.5.3. Cytotoxicity 
The cytotoxicity of the compounds were determined on the colorectal adenocarcinoma-derived cell 
line, Caco-2 (ATCC). Cells were grown in EMEM medium (ATCC) supplemented with L-glutamine, 
sodium pyruvate, 10% FBS (Invitrogen) and streptomycin/penicillin. Cells were grown until 80% 
confluent at 37 °C, in 5% CO2 and then seeded at 1000 cells/well in a 96-well plate. After 48 h to 
allow for attachment and initial proliferation of the cells, the compounds were added at the specified 
concentrations in full culture media for 24 h. As a positive control, 1% Triton-X100 in PBS was used. 
After the incubation period, the cell culture medium containing the compounds was removed to 
prevent media color changes from influencing the spectroscopic measurements. Fresh cell culture 
medium was added and the cells were left to equilibrate for 30 min. Cytotoxicity was determined using 
the XTT assay (ATCC) following the manufacturer’s instructions. The XTT reagent was incubated for 
3 h at 37 °C in the dark before measuring optical density in a Multi Skan spectrometer (Thermo 
Scientific, Waltham, MA, USA) at 475 nm and 660 nm to account for non-specific absorbance. The 
compounds were tested in triplicate at each concentration, and the results in each case are presented as 
the half maximal effective concentration (EC50). 
4. Conclusions 
There has been significant interest in the study of antimicrobial chitosan derivatives, as is evident 
from the many recent original publications [34,57–59] and reviews [27,60,61]. However, taken together, 
previous studies have not provided a clear picture of the structure-activity relationship. This is possibly 
due to a lack of uniformity in the products synthesized and also due to insufficient characterization. 
Reactions performed directly on chitosan are non-selective and usually give rise to heterogeneous products.  
In the current study, we used a systematic approach to investigate how certain chemical 
characteristics can affect the biological activity of chitosan derivatives. The results were validated by 
synthesizing each type of derivative from five different starting materials. Reproducible synthesis is 
important for this kind of investigation and, in this case, the series of cationic chitosan derivatives was 
synthesized using a TBDMS protection strategy (diTBDMS-CS) under homogeneous conditions.  
This provided full substitution on free amino groups. Two functional groups, trimethylammonium and 
the pyridinium group, were successfully inserted into the polymer either directly or with the help of  
C-2 and C-6 spacers and could be well characterized by spectroscopic techniques. The MIC values for 
the compounds revealed that the inhibitory effect was higher against S. aureus, as compared to E. coli.  
The MLC values were at most one dilution higher than the MIC values for most of the compounds, 
showing that many of the compounds were bactericidal within the measured concentration range. 
Furthermore, the derivatives with trimethylammonium as the quaternary group showed higher activity 
than the derivatives with the pyridinium group. Amongst all of the derivatives, TMC showed the 
highest antibacterial activity with MIC values as low as 4 μg/mL. On the other hand, a descending 
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order in activity could be observed with increasing spacer length in the compounds from C-2 to C-6.  
TMC displayed moderate hemolytic activity, which decreased with a decrease in DA values, while all 
of the other derivatives remained non-hemolytic within the measured concentration range. Hence, a 
decrease in activity against RBC was observed with increasing spacer length. A decrease in cytotoxicity 
with decreasing DA and increasing Mw was also observed in most cases, while no particular trend in 
cytotoxicity with changes in chain length could be derived. In spite of their cellular cytotoxicity, these 
highly active TMC, TMAC and PyAC derivatives should be considered as antibacterial agents for topical 
applications and disinfecting medical equipment. Thus, these results have increased our understanding 
of the effect of the positioning of the cationic charge, as well as the effects of DA, DS and Mw  
(for relatively low Mw chitosan derivatives) on the antibacterial properties of this class of agent. 
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